Dexamethasone inhibits the formation of multinucleated osteoclasts via down-regulation of β3 integrin expression

Archives of Pharmacal Research

Volumn 29, Issue 8, 2006, Pages 691-698

  Yong, Hee Kim ^a   Jun, Ji Hae ^a   Kyung, Mi Woo ^a   Ryoo, Hyun Mo ^a   Kim, Gwan Shik ^a   Baek, Jeong Hwa ^a  

^a Seoul National University   (South Korea)

Author keywords

Dexamethasone; Fusion; Osteoclast; Vitronectin receptor

Indexed keywords

EID: 33748373423     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/bf02968254     Document Type: Article

References (26)

1. Canalis, E., Clinical Review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab., 81, 3441-3447 (1996).
2. Crippes, B. A., Engleman, V. W., Settle, S. L., Delarco, J., Ornberg, R. L., Helfrich, M. H., Horton, M. A., and Nickols, G. A., Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology, 137, 918-924 (1996).
3. Dickerson, J. E. Jr., Steely, H. T. Jr., English-Wright, S. L., and Clark, A. F., The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp. Eye Res., 66, 731-738 (1998).
4. Duong, L. T., Lakkakorpi, P., Nakamura, I., and Rodan, G. A., Integrins and signaling in osteoclast function. Matrix Biol., 19, 97-105 (2000).
5. Duong, L. T. and Rodan, G. A., Regulation of osteoclast formation and function. Rev. Endocr. Metab. Disord., 2, 95-104 (2001).
6. Feng, X., Novack, D. V., Faccio, R., Ory, D. S., Aya, K., Boyer, M. I., McHugh, K. P., Ross, F. P., and Teitelbaum, S. L., A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J. Clin. Invest., 107, 1137-1144 (2001).
7. Hofbauer, L. C., Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur. J. Endocrinol., 141, 195-210 (1999).
8. Hultenby, K., Reinholt, F. P., and Heinegard, D., Distribution of integrin subunits on rat metaphyseal osteoclasts and osteoblasts. Eur. J. Cell Biol., 62, 86-93 (1993).
9. Inoue, M., Namba, N., Chappel, J., Teitelbaum, S. L., and Ross, F. P., Granulocyte macrophage-colony stimulating factor reciprocally regulates alphav-associated integrins on murine osteoclast precursors. Mol. Endocrinol., 12, 1955-1962 (1998).
10. Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K., and Chihara, K., Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J. Bone Miner. Res., 12, 734-741 (1997).
11. Kim, H. H., Chung, W. J., Lee, S. W., Chung, P. J., You, J. W., Kwon, H. J., Tanaka, S., and Lee, Z. H., Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation. Exp. Cell Res., 289, 368-377 (2003).
12. Kim, Y. H., Kim, G. S., and Baek, J. H., Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp. Mol. Med., 34, 145-151 (2002).
13. Lee, S. W., Kwak, H. B., Chung, W. J., Cheong, H., Kim, H. H., and Lee, Z. H., Participation of protein kinase C beta in osteoclast differentiation and function. Bone, 32, 217-227 (2003).
14. McHugh, K. P., Hodivala-Dilke, K., Zheng, M. H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F. P., Hynes, R. O., and Teitelbaum, S. L., Mice lacking â3 integrins are osteosclerotic because of dysfunctional osteoclasts. J. Clin. Invest., 105, 433-440 (2000).
15. Nagai, M. and Sato, N., Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun., 257, 719-723 (1999).
16. Nakamura, I., Tanaka, H., Rodan, G. A., and Duong, L. T., Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. Endocrinology, 139, 5182-5193 (1998).
17. Pharoah, M. and Heersche, J., Dexamethasone inhibits formation of osteoclast-like cells in bone-marrow cultures. J. Dent. Res., 65, 1006-1009 (1986).
18. Richards, C. D., Langdon, C., Deschamps, P., Pennica, D., and Shaughnessy, S. G., Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine, 12, 613-621 (2000).
19. Roodman, G. D., Advances in Bone Biology: The Osteoclast. Endocrine Rev., 17, 308-332 (1996).
20. 3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol. Rev., 208, 88-105 (2005).
21. Sexton, D. W., Blaylock, M. G., and Walsh, G. M., Human alveolar epithelial cells engulf apoptotic eosinophils by means of integrin- and phosphatidylserine receptor-dependent mechanisms: a process upregulated by dexamethasone. J. Allergy Clin. Immunol., 108, 962-969 (2001).
22. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., and Martin, T. J., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 20, 345-357 (1999).
23. Takahashi, N., Udagawa, N., and Suda, T., A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun., 256, 449-455 (1999).
24. Takuma, A., Kaneda, T., Sato, T., Ninomiya, S., Kumegawa, M., and Hakeda, Y., Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J. Biol. Chem., 278, 44667-44674 (2003).
25. Wada, S., Yasuda, S., Nagai, T., Maeda, T., Kitahama, S., Suda, S., Findlay, D. M., Iitaka, M., and Katayama, S., Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. Endocrinology, 142, 1471-1478 (2001).
26. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A., 95, 3597-3602 (1998).